AU2009259835B2 - Composite extracellular matrix materials and medical products formed therefrom - Google Patents
Composite extracellular matrix materials and medical products formed therefrom Download PDFInfo
- Publication number
- AU2009259835B2 AU2009259835B2 AU2009259835A AU2009259835A AU2009259835B2 AU 2009259835 B2 AU2009259835 B2 AU 2009259835B2 AU 2009259835 A AU2009259835 A AU 2009259835A AU 2009259835 A AU2009259835 A AU 2009259835A AU 2009259835 B2 AU2009259835 B2 AU 2009259835B2
- Authority
- AU
- Australia
- Prior art keywords
- extracellular matrix
- matrix material
- expanded
- product
- submucosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 212
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 209
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 209
- 239000011159 matrix material Substances 0.000 title claims abstract description 168
- 239000002131 composite material Substances 0.000 title claims abstract description 49
- 229940127554 medical product Drugs 0.000 title description 4
- 239000000463 material Substances 0.000 claims abstract description 368
- 210000001519 tissue Anatomy 0.000 claims abstract description 80
- 238000000034 method Methods 0.000 claims abstract description 77
- 210000004876 tela submucosa Anatomy 0.000 claims description 71
- 230000000975 bioactive effect Effects 0.000 claims description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- 230000000968 intestinal effect Effects 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 239000003102 growth factor Substances 0.000 claims description 16
- -1 hydroxide ions Chemical class 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 8
- 210000002784 stomach Anatomy 0.000 claims description 7
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 abstract description 33
- 238000002360 preparation method Methods 0.000 abstract description 17
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 239000007943 implant Substances 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000002688 persistence Effects 0.000 abstract description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 38
- 239000000654 additive Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- 239000000047 product Substances 0.000 description 30
- 239000006260 foam Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000010410 layer Substances 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 22
- 102000008186 Collagen Human genes 0.000 description 22
- 229920001436 collagen Polymers 0.000 description 20
- 238000013019 agitation Methods 0.000 description 19
- 238000001000 micrograph Methods 0.000 description 18
- 239000012498 ultrapure water Substances 0.000 description 18
- 239000012567 medical material Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 14
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000000996 additive effect Effects 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 210000000936 intestine Anatomy 0.000 description 12
- 230000002491 angiogenic effect Effects 0.000 description 11
- 238000004132 cross linking Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 9
- 230000006835 compression Effects 0.000 description 9
- 238000007906 compression Methods 0.000 description 9
- 230000018044 dehydration Effects 0.000 description 9
- 238000006297 dehydration reaction Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000645 desinfectant Substances 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 230000023597 hemostasis Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000004971 Cross linker Substances 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000008223 sterile water Substances 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 210000003195 fascia Anatomy 0.000 description 5
- 239000006261 foam material Substances 0.000 description 5
- 229960004198 guanidine Drugs 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000010008 shearing Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 4
- 230000009969 flowable effect Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 108010077465 Tropocollagen Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000002201 biotropic effect Effects 0.000 description 2
- 210000005068 bladder tissue Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229960001139 cefazolin Drugs 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000011243 crosslinked material Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000010981 drying operation Methods 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 238000013427 histology analysis Methods 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000647 polyepoxide Chemical class 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- KATAXDCYPGGJNJ-UHFFFAOYSA-N 1,3-bis(oxiran-2-ylmethoxy)propan-2-ol Chemical compound C1OC1COCC(O)COCC1CO1 KATAXDCYPGGJNJ-UHFFFAOYSA-N 0.000 description 1
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 1
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- GYNXTHOOAGYMOK-UHFFFAOYSA-N 2-hydroxybutanediamide Chemical class NC(=O)CC(O)C(N)=O GYNXTHOOAGYMOK-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000021970 Abdominal wall defect Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100170173 Caenorhabditis elegans del-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010051425 Enterocutaneous fistula Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 102100039277 Pleiotrophin Human genes 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 208000003776 Rectovaginal Fistula Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003898 enterocutaneous fistula Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002118 epoxides Chemical group 0.000 description 1
- 210000000109 fascia lata Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 239000002648 laminated material Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012978 minimally invasive surgical procedure Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 210000000562 peritoneum layer Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229930185346 proliferin Natural products 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- WFVASYNXKNXKDE-UHFFFAOYSA-K trisodium hydrogen carbonate acetate chloride Chemical class [Cl-].[Na+].C(C)(=O)[O-].[Na+].C([O-])(O)=O.[Na+] WFVASYNXKNXKDE-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7444108P | 2008-06-20 | 2008-06-20 | |
| US61/074,441 | 2008-06-20 | ||
| PCT/US2009/048168 WO2009155607A2 (en) | 2008-06-20 | 2009-06-22 | Composite extracellular matrix materials and medical products formed therefrom |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009259835A1 AU2009259835A1 (en) | 2009-12-23 |
| AU2009259835B2 true AU2009259835B2 (en) | 2014-02-20 |
Family
ID=41117620
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009259835A Ceased AU2009259835B2 (en) | 2008-06-20 | 2009-06-22 | Composite extracellular matrix materials and medical products formed therefrom |
| AU2009259828A Ceased AU2009259828B2 (en) | 2008-06-20 | 2009-06-22 | Compressible/expandable medical graft products, and methods for applying hemostasis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009259828A Ceased AU2009259828B2 (en) | 2008-06-20 | 2009-06-22 | Compressible/expandable medical graft products, and methods for applying hemostasis |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8741354B2 (enExample) |
| EP (2) | EP2307071B1 (enExample) |
| JP (2) | JP2011525140A (enExample) |
| CN (3) | CN104491928A (enExample) |
| AU (2) | AU2009259835B2 (enExample) |
| BR (2) | BRPI0914304A2 (enExample) |
| CA (2) | CA2728513C (enExample) |
| WO (2) | WO2009155607A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9788821B2 (en) * | 2005-04-29 | 2017-10-17 | Cook Biotech Incorporated | Physically modified extracellular matrix materials and uses thereof |
| US8741354B2 (en) * | 2008-06-20 | 2014-06-03 | Cook Biotech Incorporated | Composite extracellular matrix materials and medical products formed therefrom |
| US10413636B2 (en) | 2008-08-14 | 2019-09-17 | Kci Licensing, Inc. | Tissue scaffolds |
| US8652500B2 (en) | 2009-07-22 | 2014-02-18 | Acell, Inc. | Particulate tissue graft with components of differing density and methods of making and using the same |
| US8518064B2 (en) * | 2009-12-17 | 2013-08-27 | Cook Medical Technologies Llc | Method for anchoring occlusion plug |
| US8329219B2 (en) | 2009-12-22 | 2012-12-11 | Cook Biotech Incorporated | Methods for producing ECM-based biomaterials |
| US9050067B2 (en) | 2011-09-26 | 2015-06-09 | Cook Medical Technologies, LLC | Percutaneous nephrostomy plug delivery device |
| WO2013086153A1 (en) | 2011-12-09 | 2013-06-13 | Acell, Inc. | Hemostatic device |
| US10363343B2 (en) | 2012-07-05 | 2019-07-30 | Lifecell Corporation | Tissue-based drain manifolds |
| WO2014160060A1 (en) * | 2013-03-14 | 2014-10-02 | Cell and Molecular Tissue Engineering, LLC | Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods |
| US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
| US9717583B2 (en) | 2014-03-13 | 2017-08-01 | Cell and Molecular Tissue Engineering, LLC | Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods |
| US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
| WO2014149953A1 (en) * | 2013-03-15 | 2014-09-25 | Cryolife, Inc. | Methods for preparing tissue implants |
| JP6448615B2 (ja) * | 2013-03-15 | 2019-01-09 | クック・バイオテック・インコーポレイテッドＣｏｏｋ Ｂｉｏｔｅｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｅｃｍ移植組成物および方法 |
| AU2014227914B2 (en) * | 2013-03-15 | 2018-05-10 | Taris Biomedical Llc | Drug delivery devices and methods for drug delivery |
| WO2014144294A1 (en) * | 2013-03-15 | 2014-09-18 | Cook Biotech Incorporated | Methods and devices for lung volume reduction with extracellular matrix material |
| JP6461096B2 (ja) * | 2013-04-08 | 2019-01-30 | リージェンティーズ コーポレイション | 結腸切除なしに炎症性腸疾患を処置するための方法および組成物 |
| CN103272278B (zh) * | 2013-05-28 | 2015-04-15 | 北京博辉瑞进生物科技有限公司 | 一种动物源性植入性医用生物材料的制备方法 |
| CN103272277B (zh) * | 2013-05-28 | 2015-04-08 | 北京博辉瑞进生物科技有限公司 | 用于制备脱细胞小肠粘膜下层基质材料的模具 |
| US20150190227A1 (en) * | 2014-01-08 | 2015-07-09 | Cook Medical Technologies Llc | Esis heart valve support ring |
| US9610143B2 (en) | 2014-06-19 | 2017-04-04 | Osteolife Biomedical, Llc | Compressed decalcified trabecular bone grafts and tooth socket repair |
| US9775598B2 (en) | 2014-07-20 | 2017-10-03 | New York University | Anchored suture line, device and method for surgical suturing |
| AU2015321554C1 (en) * | 2014-09-25 | 2018-10-11 | Acell, Inc. | Porous foams derived from extracellular matrix, porous foam ECM medical devices, and methods of use and making thereof |
| US9801983B2 (en) | 2014-12-18 | 2017-10-31 | Cook Medical Technologies Llc | Medical devices for delivering a bioactive to a point of treatment and methods of making medical devices |
| US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
| CN110975011B (zh) * | 2015-07-29 | 2022-06-14 | 广东博与再生医学有限公司 | 一种皮肤溃疡修复基质的制备方法 |
| US20170056164A1 (en) * | 2015-09-02 | 2017-03-02 | Medtronic Vascular, Inc. | Transcatheter valve prostheses having a sealing component formed from tissue having an altered extracellular matrix |
| US10549011B2 (en) | 2015-10-26 | 2020-02-04 | Osteolife Biomedical, Llc | Bone putty and gel systems and methods |
| US20170128633A1 (en) | 2015-11-10 | 2017-05-11 | Theodore Malinin | Bioactive Implants and Methods of Making and Using |
| US11179505B2 (en) | 2016-02-11 | 2021-11-23 | Lifecell Corporation | Methods for stabilizing collagen-containing tissue products against enzymatic degradation |
| EP3471703A4 (en) | 2016-06-15 | 2020-03-18 | The General Hospital Corporation | METABOLIC MARKING AND MOLECULAR IMPROVEMENT OF BIOLOGICAL MATERIALS USING BIOORTHOGONAL REACTIONS |
| WO2018009428A1 (en) * | 2016-07-05 | 2018-01-11 | Lifecell Corporation | Tissue matrices incorporating multiple tissue types |
| CN107007870B (zh) * | 2017-03-03 | 2019-11-19 | 北京博辉瑞进生物科技有限公司 | 一种生物止血材料、制备方法及其应用 |
| KR102387327B1 (ko) * | 2017-04-28 | 2022-04-15 | 쿡 메디컬 테크놀러지스 엘엘씨 | 활발한 출혈을 갖는 위장 병변에 대한 이중양식 치료 방법 및 조성물 |
| US11679177B2 (en) | 2017-08-08 | 2023-06-20 | Baxter International Inc. | Polymeric compositions, delivery devices, and methods |
| US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
| CN109224132A (zh) * | 2018-09-17 | 2019-01-18 | 上海大学 | 多层复合腹壁修复补片支架及其制备方法 |
| CN111195173A (zh) * | 2018-11-19 | 2020-05-26 | 江苏昌吉永生物科技股份有限公司 | 一种注射型止血涂覆器及其制备方法 |
| CN111249518B (zh) | 2018-12-01 | 2021-03-05 | 浙江大学 | 一种止血组合物及其制备方法 |
| JP2022516562A (ja) * | 2019-01-07 | 2022-02-28 | ミロマトリックス メディカル インコーポレイテッド | 細胞外マトリクスの脱水方法およびそれにより形成される粒子 |
| CN110038163B (zh) * | 2019-04-16 | 2021-11-05 | 上海大学 | 一种用于修复腹壁缺损的水凝胶复合生物补片制备方法 |
| WO2020242942A1 (en) | 2019-05-24 | 2020-12-03 | Cook Biotech Incorporated | Nasal septum cartilage compositions and methods |
| US11826490B1 (en) | 2020-12-29 | 2023-11-28 | Acell, Inc. | Extracellular matrix sheet devices with improved mechanical properties and method of making |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030051735A1 (en) * | 2001-07-26 | 2003-03-20 | Cook Biotech Incorporated | Vessel closure member, delivery apparatus, and method of inserting the member |
| US20030167088A1 (en) * | 1998-06-05 | 2003-09-04 | Organogenesis, Inc. | Bioengineered vascular graft prostheses |
| US20080004657A1 (en) * | 2005-04-29 | 2008-01-03 | Obermiller F J | Volumetric grafts for treatment of fistulae and related methods and systems |
| WO2008067085A2 (en) * | 2006-10-23 | 2008-06-05 | Cook Biotech Incorporated | Processed ecm materials with enhanced component profiles |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB731501A (en) | 1952-08-08 | 1955-06-08 | Ethicon Suture Lab Inc | Preparation of collagenous material |
| FR1358465A (fr) * | 1963-02-21 | 1964-04-17 | Procédé de traitement de tissus animaux, en particulier en vue de la séparation de polysaccharides | |
| US3551560A (en) | 1967-10-02 | 1970-12-29 | Heinrich F Thiele | Process of reconstructing tendons,cartilage,nerve sheaths,and products |
| FR2516927B1 (fr) * | 1981-11-26 | 1986-05-23 | Merieux Fond | Procede de preparation industrielle de materiaux collageniques a partir de tissus placentaires humains, materiaux collageniques humains obtenus, leur application comme biomateriaux |
| ATE109491T1 (de) * | 1988-03-11 | 1994-08-15 | Chemokol G B R Ing Buero Fuer | Verfahren zur herstellung von kollagenmembranen für hämostase, wundbehandlung und implantate. |
| US6350274B1 (en) * | 1992-05-11 | 2002-02-26 | Regen Biologics, Inc. | Soft tissue closure systems |
| US5523291A (en) * | 1993-09-07 | 1996-06-04 | Datascope Investment Corp. | Injectable compositions for soft tissue augmentation |
| AU700584C (en) * | 1994-08-12 | 2002-03-28 | Meadox Medicals, Inc. | Vascular graft impregnated with a heparin-containing collagen sealant |
| US5752974A (en) | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
| US6666892B2 (en) | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
| US5993844A (en) * | 1997-05-08 | 1999-11-30 | Organogenesis, Inc. | Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix |
| US6090996A (en) | 1997-08-04 | 2000-07-18 | Collagen Matrix, Inc. | Implant matrix |
| US8882850B2 (en) * | 1998-12-01 | 2014-11-11 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
| DK1051206T3 (da) * | 1998-12-01 | 2008-11-24 | Cook Biotech Inc | En multi-formet medicinsk anordning af kollagenbaseret biomateriale |
| AU1801899A (en) | 1998-12-03 | 2000-06-19 | Histatek, Llc | Small peptides and methods for treatment of asthma and inflammation |
| US6376244B1 (en) | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
| US6471723B1 (en) | 2000-01-10 | 2002-10-29 | St. Jude Medical, Inc. | Biocompatible prosthetic tissue |
| US6893462B2 (en) * | 2000-01-11 | 2005-05-17 | Regeneration Technologies, Inc. | Soft and calcified tissue implants |
| DE10025367A1 (de) * | 2000-05-23 | 2001-12-13 | Basf Ag | Frisch gefälltes CuO als Katalysator für die Trialkoxysilan-Synthese |
| CA2777791A1 (en) * | 2000-09-18 | 2002-03-21 | Organogenesis Inc. | Methods for treating a patient using a bioengineered flat sheet graft prostheses |
| US6685626B2 (en) * | 2001-02-02 | 2004-02-03 | Regeneration Technologies, Inc. | Compositions, devices, methods, and kits for induction of adhesions |
| AU2002320182B2 (en) * | 2001-06-29 | 2008-02-21 | Cook Biotech Incorporated | Porous sponge matrix medical devices and methods |
| US20050281999A1 (en) * | 2003-03-12 | 2005-12-22 | Petritech, Inc. | Structural and other composite materials and methods for making same |
| US8021692B2 (en) * | 2003-08-25 | 2011-09-20 | Cook Biotech Incorporated | Graft materials containing bioactive substances, and methods for their manufacture |
| US20050117339A1 (en) | 2003-12-01 | 2005-06-02 | Frank Pan | Illuminating light string arrangement |
| GB2449784B8 (en) * | 2004-02-09 | 2009-04-29 | Cook Biotech Inc | Stent graft devices having collagen coating. |
| JP2007532153A (ja) * | 2004-03-31 | 2007-11-15 | クック インコーポレイテッド | Ｅｃｍを基材としたグラフト材料 |
| EP1787664A4 (en) * | 2004-08-24 | 2011-08-24 | Gunze Kk | METHOD FOR PRODUCING COLLAGEN SPONGE, METHOD FOR PRODUCING ARTIFICIAL SKIN, ARTIFICIAL SKIN, AND CELL TISSUE CULTURE SUBSTRATE |
| US9138445B2 (en) * | 2005-03-09 | 2015-09-22 | Cook Biotech Incorporated | Medical graft materials with adherent extracellular matrix fibrous mass |
| US9788821B2 (en) * | 2005-04-29 | 2017-10-17 | Cook Biotech Incorporated | Physically modified extracellular matrix materials and uses thereof |
| US9271817B2 (en) * | 2005-07-05 | 2016-03-01 | Cook Biotech Incorporated | Tissue augmentation devices and methods |
| US20070029247A1 (en) * | 2005-08-04 | 2007-02-08 | Compost And Technology Solutions, Inc. | Apparatus to separate waste from wastewater |
| JP5208752B2 (ja) | 2005-10-18 | 2013-06-12 | オーガノジェネシス・インコーポレイテッド | 抗菌性コラーゲン構築物 |
| EP1987134A4 (en) * | 2006-02-10 | 2012-08-01 | Tengion Inc | EQUIPMENT FOR ORGANIC DESIGN AND AUGMENTATION |
| US8741354B2 (en) * | 2008-06-20 | 2014-06-03 | Cook Biotech Incorporated | Composite extracellular matrix materials and medical products formed therefrom |
-
2009
- 2009-06-22 US US12/488,996 patent/US8741354B2/en active Active
- 2009-06-22 JP JP2011514890A patent/JP2011525140A/ja active Pending
- 2009-06-22 CA CA2728513A patent/CA2728513C/en not_active Expired - Fee Related
- 2009-06-22 CN CN201410708559.XA patent/CN104491928A/zh active Pending
- 2009-06-22 BR BRPI0914304A patent/BRPI0914304A2/pt active Search and Examination
- 2009-06-22 JP JP2011514887A patent/JP2011525139A/ja active Pending
- 2009-06-22 AU AU2009259835A patent/AU2009259835B2/en not_active Ceased
- 2009-06-22 BR BRPI0914303A patent/BRPI0914303A2/pt active Search and Examination
- 2009-06-22 EP EP09767914.6A patent/EP2307071B1/en not_active Not-in-force
- 2009-06-22 CN CN2009801299075A patent/CN102215883A/zh active Pending
- 2009-06-22 WO PCT/US2009/048168 patent/WO2009155607A2/en not_active Ceased
- 2009-06-22 AU AU2009259828A patent/AU2009259828B2/en not_active Ceased
- 2009-06-22 CN CN200980129908.XA patent/CN102112162B/zh not_active Expired - Fee Related
- 2009-06-22 WO PCT/US2009/048152 patent/WO2009155600A2/en not_active Ceased
- 2009-06-22 US US12/488,974 patent/US20090318934A1/en not_active Abandoned
- 2009-06-22 EP EP09767907.0A patent/EP2358409B1/en not_active Not-in-force
- 2009-06-22 CA CA2734560A patent/CA2734560C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030167088A1 (en) * | 1998-06-05 | 2003-09-04 | Organogenesis, Inc. | Bioengineered vascular graft prostheses |
| US20030051735A1 (en) * | 2001-07-26 | 2003-03-20 | Cook Biotech Incorporated | Vessel closure member, delivery apparatus, and method of inserting the member |
| US20080004657A1 (en) * | 2005-04-29 | 2008-01-03 | Obermiller F J | Volumetric grafts for treatment of fistulae and related methods and systems |
| WO2008067085A2 (en) * | 2006-10-23 | 2008-06-05 | Cook Biotech Incorporated | Processed ecm materials with enhanced component profiles |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2728513C (en) | 2016-03-15 |
| AU2009259828A1 (en) | 2009-12-23 |
| CA2734560A1 (en) | 2009-12-23 |
| US20090317469A1 (en) | 2009-12-24 |
| WO2009155607A2 (en) | 2009-12-23 |
| WO2009155600A3 (en) | 2010-09-30 |
| WO2009155607A3 (en) | 2010-09-10 |
| CN102112162B (zh) | 2014-12-24 |
| CA2734560C (en) | 2018-10-23 |
| CN104491928A (zh) | 2015-04-08 |
| WO2009155600A2 (en) | 2009-12-23 |
| CA2728513A1 (en) | 2009-12-23 |
| CN102215883A (zh) | 2011-10-12 |
| BRPI0914304A2 (pt) | 2015-10-13 |
| US20090318934A1 (en) | 2009-12-24 |
| EP2307071B1 (en) | 2015-08-12 |
| JP2011525139A (ja) | 2011-09-15 |
| EP2358409B1 (en) | 2017-01-18 |
| US8741354B2 (en) | 2014-06-03 |
| AU2009259828B2 (en) | 2014-05-08 |
| JP2011525140A (ja) | 2011-09-15 |
| CN102112162A (zh) | 2011-06-29 |
| AU2009259835A1 (en) | 2009-12-23 |
| EP2358409A2 (en) | 2011-08-24 |
| EP2307071A2 (en) | 2011-04-13 |
| BRPI0914303A2 (pt) | 2015-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009259835B2 (en) | Composite extracellular matrix materials and medical products formed therefrom | |
| US9788821B2 (en) | Physically modified extracellular matrix materials and uses thereof | |
| JP5964904B2 (ja) | 増強した成分プロファイルを有する加工したｅｃｍ材料 | |
| US8784890B2 (en) | Methods for producing ECM-based biomaterials | |
| CA2717619C (en) | Graft materials and methods for staged delivery of bioactive components | |
| US20100266654A1 (en) | Medical composition including an extracellular matrix particulate | |
| US20090142400A1 (en) | Analgesic coated medical product | |
| WO2010088678A2 (en) | Medical bead products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |